Literature DB >> 14999414

[Sterility of non-preserved autologous serum drops for treatment of persistent corneal epithelial defects].

R Sauer1, K Blüthner, B Seitz.   

Abstract

PURPOSE: To investigate the sterility of non-preserved autologous serum drops in hospitalized patients with persistent corneal epithelial defects.
METHODS: Thirty patients with persistent corneal epithelial defects (aged between 28 and 85, mean 67+/-14 years) were treated with autologous serum drops in five different wards of a university eye hospital between October 2001 and March 2002. After centrifugation of freshly collected autologous blood, the serum was stored in sterile drop bottles at refrigerator temperature (7 degrees C) and applied undiluted every 1 or 2 h up to 7 days. Using blood, chocolate, endo, and Sabouraud agar media, we assessed the sterility of autologous serum drops on the day before application and on the 4th and 7th days. Examinations performed on the 1st and 4th days included 40 autologous serum drops each and on the 7th day 120 samples (40 serum drops, 40 bottle tops, and 40 bottle bottoms). The agar media for bacterial examination were read after 48 h of incubation time, and those for fungal examination were read after 21 days. All patients had received topical autologous serum therapy and prophylactic antibiotic drops for at least 7 days.
RESULTS: The time period of autologous serum treatment ranged from 7 to 28 (10+/-5) days. On the 1st and 4th days autologous serum drops were sterile. On the 7th day, 3 of 40 (7.5%) samples were contaminated with Staphylococcus epidermidis. Two of these contaminations were due to a combined serum drop and bottle top contamination (5%). A third case resulted from additional bottle bottom contamination (2.5%). None of the samples examined showed signs of fungal infection. During application of autologous serum as well as during the follow-up period no patient showed any symptoms of ocular infection.
CONCLUSIONS: The application of autologous serum has proven to be a practicable therapy in patients with persistent corneal epithelial defects. When the drops are applied by trained personnel, the absence of contamination can be ensured up to the 4th day. By additional application of prophylactic antibiotic drops, infections may be avoided even if refrigerated non-preserved autologous serum is used up to 7 days.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14999414     DOI: 10.1007/s00347-003-0962-4

Source DB:  PubMed          Journal:  Ophthalmologe        ISSN: 0941-293X            Impact factor:   1.059


  31 in total

1.  [Techniques for reconstruction of the corneal surface by transplantation of preserved human amniotic membrane].

Authors:  F E Kruse; K Rohrschneider; H E Völcker
Journal:  Ophthalmologe       Date:  1999-10       Impact factor: 1.059

2.  Corneal sensitivity and burning sensation. Comparing topical ketorolac and diclofenac.

Authors:  B Seitz; K Sorken; L D LaBree; J J Garbus; P J McDonnell
Journal:  Arch Ophthalmol       Date:  1996-08

3.  Topical treatment with nerve growth factor for corneal neurotrophic ulcers.

Authors:  A Lambiase; P Rama; S Bonini; G Caprioglio; L Aloe
Journal:  N Engl J Med       Date:  1998-04-23       Impact factor: 91.245

4.  [Autologous serum-eye-drops for ocular surface disorders. A literature review and recommendations for their application].

Authors:  G Geerling; D Hartwig
Journal:  Ophthalmologe       Date:  2002-12       Impact factor: 1.059

5.  Gross factors in treatment of nonhealing corneal ulcers and recurrent erosions.

Authors:  G Singh; C S Foster
Journal:  Cornea       Date:  1989       Impact factor: 2.651

6.  Presence of epidermal growth factor in human tears.

Authors:  Y Ohashi; M Motokura; Y Kinoshita; T Mano; H Watanabe; S Kinoshita; R Manabe; K Oshiden; C Yanaihara
Journal:  Invest Ophthalmol Vis Sci       Date:  1989-08       Impact factor: 4.799

7.  Nonmechanical excimer laser penetrating keratoplasty for perforated or predescemetal corneal ulcers.

Authors:  M Küchle; B Seitz; A Langenbucher; G O Naumann
Journal:  Ophthalmology       Date:  1999-11       Impact factor: 12.079

8.  Topical treatment with nerve growth factor for neurotrophic keratitis.

Authors:  S Bonini; A Lambiase; P Rama; G Caprioglio; L Aloe
Journal:  Ophthalmology       Date:  2000-07       Impact factor: 12.079

9.  Conjunctival flaps.

Authors:  A M Alino; H D Perry; A J Kanellopoulos; E D Donnenfeld; E K Rahn
Journal:  Ophthalmology       Date:  1998-06       Impact factor: 12.079

10.  Epidermal growth factor stimulates corneal epithelial cell attachment to fibronectin through a fibronectin receptor system.

Authors:  T Nishida; M Nakamura; J Murakami; H Mishima; T Otori
Journal:  Invest Ophthalmol Vis Sci       Date:  1992-07       Impact factor: 4.799

View more
  7 in total

1.  [Classification of biomedical research reports as a reference for evidence-based medicine in ophthalmology. A survey considering as example the journal Der Ophthalmologe].

Authors:  H P N Scholl; M Fleckenstein; T U Krohne; F G Holz
Journal:  Ophthalmologe       Date:  2005-12       Impact factor: 1.059

Review 2.  [Albumin eye drops for treatment of ocular surface diseases].

Authors:  J D Unterlauft; M Kohlhaas; I Hofbauer; K Kasper; G Geerling
Journal:  Ophthalmologe       Date:  2009-10       Impact factor: 1.059

3.  Stability of epidermal growth factor, fibronectin, and alpha-2-macroglobulin in canine serum under different storage conditions.

Authors:  Cecile Briffod; Christian Bédard; Maria Vanore
Journal:  Can J Vet Res       Date:  2019-10       Impact factor: 1.310

4.  [Autologous serum versus hyaluronic acid eye drops for the treatment of corneal erosions after vitrectomy in diabetic patients. A prospective randomized study].

Authors:  S Schulze; W Sekundo; P Kroll
Journal:  Ophthalmologe       Date:  2005-09       Impact factor: 1.059

5.  [Conservative and surgical treatment of neurotrophic keratopathy].

Authors:  B Seitz; M Grüterich; C Cursiefen; F E Kruse
Journal:  Ophthalmologe       Date:  2005-01       Impact factor: 1.059

Review 6.  Autologous serum eye drops for ocular surface disorders.

Authors:  G Geerling; S Maclennan; D Hartwig
Journal:  Br J Ophthalmol       Date:  2004-11       Impact factor: 4.638

7.  [Manufacture of autologous serum eye drops for out-patient therapy : cooperation between ophthalmic clinic and transfusion medicine department].

Authors:  T Dietrich; V Weisbach; B Seitz; C Jacobi; F E Kruse; R Eckstein; C Cursiefen
Journal:  Ophthalmologe       Date:  2008-11       Impact factor: 1.059

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.